Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.82 USD
−197.88 M USD
781.37 M USD
104.28 M
About Apellis Pharmaceuticals, Inc.
Sector
Industry
CEO
Cedric Francois
Website
Headquarters
Waltham
Founded
2009
ISIN
US03753U1060
FIGI
BBG007KGRPY4
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
APLS5052553
Apellis Pharmaceuticals, Inc. 3.5% 15-SEP-2026Yield to maturity
—
Maturity date
Sep 15, 2026
See all APLS bonds
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange Apellis Pharmaceuticals, Inc. stocks are traded under the ticker APLS.
We've gathered analysts' opinions on Apellis Pharmaceuticals, Inc. future price: according to them, APLS price has a max estimate of 60.00 USD and a min estimate of 19.00 USD. Watch APLS chart and read a more detailed Apellis Pharmaceuticals, Inc. stock forecast: see what analysts think of Apellis Pharmaceuticals, Inc. and suggest that you do with its stocks.
APLS reached its all-time high on Jun 30, 2023 with the price of 89.15 USD, and its all-time low was 17.45 USD and was reached on Jul 7, 2025. View more price dynamics on APLS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Apellis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Apellis Pharmaceuticals, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
APLS earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.47 USD resulting in a 29.11% surprise. The estimated earnings for the next quarter are 1.59 USD per share. See more details about Apellis Pharmaceuticals, Inc. earnings.
Apellis Pharmaceuticals, Inc. revenue for the last quarter amounts to 171.39 M USD, despite the estimated figure of 185.46 M USD. In the next quarter, revenue is expected to reach 388.80 M USD.
APLS net income for the last quarter is −42.15 M USD, while the quarter before that showed −92.22 M USD of net income which accounts for 54.30% change. Track more Apellis Pharmaceuticals, Inc. financial stats to get the full picture.
No, APLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 8, 2025, the company has 710 employees. See our rating of the largest employees — is Apellis Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Apellis Pharmaceuticals, Inc. EBITDA is −188.26 M USD, and current EBITDA margin is −20.88%. See more stats in Apellis Pharmaceuticals, Inc. financial statements.
Like other stocks, APLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Apellis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.